# DESCRIPTION

## TECHNICAL FIELD

- introduce recombinant Gallid herpesvirus 3 vector

## BACKGROUND

- describe Marek's disease
- describe Marek's disease virus-1
- describe Gallid herpesvirus 2
- describe MDV-1 replication
- describe MD mortality rate
- describe live vaccines against MD
- describe HVT as a recombinant vaccine vector
- describe limitations of HVT vector
- describe GaHV3 as a vaccine vector
- describe SB-1 strain of GaHV3
- describe bivalent vaccines containing SB-1 and HVT
- describe need for additional vector platforms
- describe challenges in controlling IBDV
- describe need for bivalent MDV/IBDV vaccines

## SUMMARY OF THE INVENTION

- describe recombinant Gallid herpesvirus 3 vector
- describe insertion of heterologous polynucleotides
- describe expression of at least one antigen
- describe preferred antigens
- describe expression cassette
- describe promoter options
- describe vaccine composition
- describe further Marek's disease virus vector
- describe recombinant Marek's disease virus vector
- describe administration of vaccine
- describe isolated DNA encoding vector
- describe bacterial artificial chromosome
- describe use of vaccine in avian species
- describe protection against diseases
- describe administration routes
- describe method of treating avian species
- describe recombinant Gallid herpesvirus 3 vector with markers

## DETAILED DESCRIPTION

- define general embodiments
- clarify singular and plural forms
- define animal
- specify avian species
- define poultry
- specify preferred avian species
- define nucleic acid
- explain nucleotide and polynucleotide
- describe nucleic acid sequence
- define genomic DNA
- define genomic RNA
- explain gene
- describe heterologous polynucleotide
- define recombinant viral vector
- specify recombinant Gallid herpesvirus 3 vector
- describe modification of polynucleotide or protein
- define protein
- explain antigen
- describe immunogen
- specify antigen of an avian pathogen
- define immunogenic protein or peptide
- explain conservative variation
- describe epitope
- explain antigenic determinant site
- describe conformational epitope
- specify linear epitope
- explain blocking of antibody binding
- conclude definitions
- define immunological response
- describe avian pathogen
- define insertion site
- explain nonessential region
- define intergenic locus
- describe expression cassette
- define promoter
- explain transcription termination region
- define identical or percent identity
- describe vaccine or immunogenic composition
- define vaccinating
- explain polyvalent vaccine
- define Marek's disease virus
- describe isolated DNA
- define bacterial artificial chromosome
- explain pharmaceutically acceptable carrier
- define antibody
- describe avian influenza virus
- explain infectious bursal disease virus
- describe New castle disease virus
- explain infectious laryngotracheitis virus
- describe avian infectious bronchitis virus
- explain intergenic locus between UL3 and UL4
- describe intergenic locus between UL21 and UL22
- explain insertion of heterologous polynucleotide
- describe suitable insertion site
- explain expression of antigen of avian pathogen

### Recombinant Gallid Herpesvirus 3 (GaHV3; MDV-2) Vector

- introduce recombinant GaHV3 vector
- describe vector composition
- specify intergenic loci UL3/UL4 and UL21/UL22
- define heterologous polynucleotide insertion
- list avian pathogens
- specify IBDV as preferred antigen
- describe VP2 protein of IBDV
- define sequence similarity and identity
- specify SEQ ID NO: 10 and SEQ ID NO: 6
- describe immunogenic fragment
- specify ILTV glycoprotein E, I, and B
- describe sequence similarity and identity
- specify SEQ ID NO: 31, SEQ ID NO: 32, and SEQ ID NO: 33
- describe immunogenic fragment
- specify NDV fusion protein and hemagglutinin neuraminidase
- describe sequence similarity and identity
- specify SEQ ID NO: 34 and SEQ ID NO: 35
- describe immunogenic fragment
- specify avian influenza A serotype H5, H7, and H9 hemagglutinin
- describe sequence similarity and identity
- specify SEQ ID NO: 36, SEQ ID NO: 37, and SEQ ID NO: 38
- describe immunogenic fragment
- specify avian influenza A serotype H5N1 neuraminidase
- describe sequence similarity and identity
- specify SEQ ID NO: 39
- describe immunogenic fragment
- specify S1 or S2 glycoprotein of IBV
- describe sequence similarity and identity
- specify SEQ ID NO: 40
- describe immunogenic fragment
- define allelic variant
- describe codon optimization
- specify host species
- describe viral gene modification
- specify optimization of viral protein or polynucleotide
- describe recombinant vector with multiple heterologous polynucleotides
- specify two or three heterologous polynucleotides
- describe insertion sites
- specify expression cassettes
- describe regulatory sequences for expression

### An Intermediate Recombinant Gallid Herpesvirus 3 (GaHV3; MDV-2) Vector Comprising One or More Maker(s)

- define intermediate product
- describe recombinant Gallid herpesvirus 3 vector
- specify marker(s) inserted into intergenic loci
- list types of markers
- describe function of marker

### Methods for Producing a Recombinant Gallid Herpesvirus 3 (GaHV3; MDV-2) Vector

- introduce method for producing recombinant Gallid herpesvirus 3 vector
- describe step of providing Gallid herpesvirus 3 vector
- describe step of inserting heterologous polynucleotide(s)
- describe step of amplifying Gallid herpesvirus 3 vector
- specify Gallid herpesvirus 3 vector used
- describe alternative method of producing recombinant Gallid herpesvirus 3 vector
- describe step of replacing marker(s) with expression cassette
- describe step of amplifying Gallid herpesvirus 3 vector
- specify site-specific recombinase technology used
- describe construction of recombinant Gallid herpesvirus-3 vector
- describe use of bacterial artificial chromosome (BAC) or P1-derived artificial chromosome (PAC)
- describe steps of cloning and transfecting
- describe steps of isolating and amplifying recombinant Gallid herpesvirus 3 vector
- describe production of recombinant Gallid herpesvirus-3 vector in primary chicken embryo fibroblasts
- describe storage of recombinant Gallid herpesvirus-3 vector
- describe use of recombinant Gallid herpesvirus-3 vector as vaccine

### Vaccines

- introduce vaccine comprising recombinant Gallid herpesvirus 3 vector
- describe vaccine composition
- specify pharmaceutically or veterinarily acceptable carrier, excipient or adjuvant
- describe alternative vaccine composition
- specify further Marek's disease virus (MDV) vector
- describe types of further MDV vectors
- specify recombinant MDV vector
- describe types of recombinant MDV vectors
- describe second recombinant Gallid herpesvirus 3 vector
- specify differences between first and second recombinant Gallid herpesvirus 3 vectors
- describe administration of vaccine
- specify adjuvants used
- describe types of adjuvants
- specify pharmaceutically acceptable carriers
- describe types of pharmaceutically acceptable carriers
- describe vaccine formulation
- specify buffers used
- describe types of buffers
- specify antioxidants used
- describe types of antioxidants
- specify preservatives used
- describe administration routes
- describe vaccine storage

### Use of the Vaccine

- introduce vaccine method
- prime-boost administration regimen
- specify avian species
- specify avian pathogens
- describe treatment method
- specify administration routes
- specify administration timing
- provide embodiment example

## EXAMPLES

- clone galK expression cassette into SB-1 virus genome
- describe homologous recombination technique
- exemplify insertion sites UL3/4, UL10/11 and UL21/22
- clone IBDV VP2 expressing cassette into SB-1 virus genome
- replace galK expression cassette with VP2 expression cassette
- confirm integration of VP2 expression cassette

### Cell Culture and Virus Propagation

- prepare chicken embryonic fibroblasts (CEF)
- propagate DF-1 and DT40 cells
- transfect BAC DNA into CEF
- titrate SB-1 vaccine viruses

### Virus Growth Curve Studies

- quantify SB-1 genome copy numbers using real-time PCR

### Serum Neutralization Test

- perform serum neutralization test using D78 strain of IBDV

### Statistical Analysis

- analyze data using linear model and ANOVA tests

### Analysis of Different Loci to Insert an Expression Cassette

- examine potential of SB-1 as a novel recombinant vector
- test intergenic regions for inserting expression cassettes

### Example 2

- construct pSB-1-UL3/4VP2, pSB-1-UL10/11VP2 and pSB-1-
- compare replication of recombinant and parental SB-1 viruses
- conclude that UL3/4 locus has the least effect on growth rate

### Example 3

- examine immunogenic potential of VP2 protein delivered by recombinant SB-1 vector

### Vaccine Development Against IBDV: Immunization Study

- introduce experimental design
- describe animal housing and care
- outline vaccination procedure
- detail blood sampling schedule
- describe immunogenicity assessment
- present results of neutralizing antibody production
- compare antibody levels between groups
- summarize findings
- introduce Example 4
- describe challenge study design
- outline vaccination procedure
- detail challenge procedure
- describe clinical sign scoring
- present results of challenge study
- summarize findings
- introduce Example 5
- describe interference study design
- outline vaccination procedure
- detail blood sampling schedule
- describe virus neutralization assay
- present results of virus neutralization assay
- compare antibody levels between groups
- summarize findings
- introduce invention
- describe recombinant Gallid herpesvirus 3 vector
- outline vector construction
- describe vector components
- detail antigen expression
- describe vector applications
- outline vaccine composition
- describe vaccine administration
- detail vaccine efficacy
- summarize invention
- describe isolated DNA encoding vector
- describe bacterial artificial chromosome
- outline vaccine use
- describe method of treating avian species
- detail administration routes
- summarize method

